⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage ivb salivary gland cancer

Every month we try and update this database with for stage ivb salivary gland cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00507767
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
dasatinib
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00096512
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
sorafenib tosyl...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT02035527
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Oral ...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
sorafenib tosyl...
cisplatin
docetaxel
Correlative Stu...
18 Years - Ohio State University Comprehensive Cancer Center
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00507767
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
dasatinib
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation TherapyNCT02123511
Mucositis
Oral Complicati...
Recurrent Adeno...
Recurrent Basal...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Mucoe...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage I Adenoid...
Stage I Basal C...
Stage I Lymphoe...
Stage I Lymphoe...
Stage I Mucoepi...
Stage I Salivar...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Verruco...
Stage I Verruco...
Stage II Adenoi...
Stage II Basal ...
Stage II Lympho...
Stage II Lympho...
Stage II Mucoep...
Stage II Saliva...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Verruc...
Stage II Verruc...
Stage III Adeno...
Stage III Basal...
Stage III Lymph...
Stage III Lymph...
Stage III Mucoe...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage III Verru...
Stage IV Lympho...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Lymph...
Stage IVA Mucoe...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Lymph...
Stage IVB Mucoe...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Lymph...
Stage IVC Mucoe...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
acetylcysteine
placebo
quality-of-life...
questionnaire a...
18 Years - Mayo Clinic
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.NCT01469429
Metastatic Squa...
Salivary Gland ...
Stage 0 Hypopha...
Stage 0 Larynge...
Stage 0 Lip and...
Stage 0 Nasopha...
Stage 0 Orophar...
Stage 0 Paranas...
Stage I Salivar...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Verruco...
Stage I Verruco...
Stage II Saliva...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Verruc...
Stage II Verruc...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage III Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Oral ...
Stage IVA Squam...
Stage IVA Nasal...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Oral ...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Oral ...
Stage IVC Squam...
Paranasal Sinus...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
placebo
laboratory biom...
questionnaire a...
chemoprevention
chemoprevention
placebo
21 Years - Ohio State University Comprehensive Cancer Center
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerNCT00114283
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
lapatinib ditos...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerNCT00126607
High-grade Sali...
Recurrent Saliv...
Salivary Gland ...
Salivary Gland ...
Salivary Gland ...
Stage IVA Saliv...
Stage IVB Saliv...
Stage IVC Saliv...
trastuzumab
laboratory biom...
18 Years - National Cancer Institute (NCI)
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By SurgeryNCT01220583
Head and Neck C...
cisplatin
3-dimensional c...
intensity-modul...
18 Years - Radiation Therapy Oncology Group
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabNCT00939627
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
cetuximab
placebo
sorafenib tosyl...
laboratory biom...
quality-of-life...
18 Years - National Cancer Institute (NCI)
Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerNCT02245100
Metastatic Squa...
Salivary Gland ...
Stage IIIA Non-...
Stage IIIB Non-...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
Cytology specim...
Laboratory biom...
18 Years - Thomas Jefferson University
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497
Anaplastic Thyr...
Insular Thyroid...
Metastatic Para...
Recurrent Adeno...
Recurrent Basal...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Non-s...
Recurrent Parat...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Thyro...
Recurrent Verru...
Stage III Folli...
Stage III Papil...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage IIIB Non-...
Stage IV Lympho...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Esthe...
Stage IVA Folli...
Stage IVA Inver...
Stage IVA Lymph...
Stage IVA Midli...
Stage IVA Mucoe...
Stage IVA Papil...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Esthe...
Stage IVB Folli...
Stage IVB Inver...
Stage IVB Lymph...
Stage IVB Midli...
Stage IVB Mucoe...
Stage IVB Papil...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Esthe...
Stage IVC Folli...
Stage IVC Inver...
Stage IVC Lymph...
Stage IVC Midli...
Stage IVC Mucoe...
Stage IVC Papil...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Thryoid Gland N...
Thyroid Gland M...
Tongue Cancer
Untreated Metas...
gefitinib
- National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00507767
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
dasatinib
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckNCT00033618
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
ixabepilone
laboratory biom...
18 Years - National Cancer Institute (NCI)
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.NCT01469429
Metastatic Squa...
Salivary Gland ...
Stage 0 Hypopha...
Stage 0 Larynge...
Stage 0 Lip and...
Stage 0 Nasopha...
Stage 0 Orophar...
Stage 0 Paranas...
Stage I Salivar...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Squamou...
Stage I Verruco...
Stage I Verruco...
Stage II Saliva...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Squamo...
Stage II Verruc...
Stage II Verruc...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage III Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Oral ...
Stage IVA Squam...
Stage IVA Nasal...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Oral ...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Oral ...
Stage IVC Squam...
Paranasal Sinus...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
placebo
laboratory biom...
questionnaire a...
chemoprevention
chemoprevention
placebo
21 Years - Ohio State University Comprehensive Cancer Center
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675
Adult Giant Cel...
Adult Glioblast...
Adult Gliosarco...
Male Breast Can...
Metastatic Squa...
Recurrent Adeno...
Recurrent Adult...
Recurrent Basal...
Recurrent Colon...
Recurrent Esthe...
Recurrent Hypop...
Recurrent Inver...
Recurrent Laryn...
Recurrent Lip a...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Nasop...
Recurrent Non-s...
Recurrent Oroph...
Recurrent Pancr...
Recurrent Paran...
Recurrent Recta...
Recurrent Renal...
Recurrent Saliv...
Stage IIIA Brea...
Stage IIIA Non-...
Stage IIIB Brea...
Stage IIIB Non-...
Stage IIIC Brea...
Stage IV Breast...
Stage IV Non-sm...
Stage IV Pancre...
Stage IV Renal ...
Stage IVA Colon...
Stage IVA Recta...
Stage IVA Saliv...
Stage IVB Colon...
Stage IVB Saliv...
Stage IVC Saliv...
Tongue Cancer
Unspecified Adu...
18F-fludeoxyglu...
18F-FPPRGD2
18 Years - Stanford University
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00095628
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IV Verruc...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVC Saliv...
Stage IVC Squam...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497
Anaplastic Thyr...
Insular Thyroid...
Metastatic Para...
Recurrent Adeno...
Recurrent Basal...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Non-s...
Recurrent Parat...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Thyro...
Recurrent Verru...
Stage III Folli...
Stage III Papil...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage IIIB Non-...
Stage IV Lympho...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Esthe...
Stage IVA Folli...
Stage IVA Inver...
Stage IVA Lymph...
Stage IVA Midli...
Stage IVA Mucoe...
Stage IVA Papil...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Esthe...
Stage IVB Folli...
Stage IVB Inver...
Stage IVB Lymph...
Stage IVB Midli...
Stage IVB Mucoe...
Stage IVB Papil...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Esthe...
Stage IVC Folli...
Stage IVC Inver...
Stage IVC Lymph...
Stage IVC Midli...
Stage IVC Mucoe...
Stage IVC Papil...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Thryoid Gland N...
Thyroid Gland M...
Tongue Cancer
Untreated Metas...
gefitinib
- National Cancer Institute (NCI)
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabNCT00939627
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
Untreated Metas...
cetuximab
placebo
sorafenib tosyl...
laboratory biom...
quality-of-life...
18 Years - National Cancer Institute (NCI)
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT00095628
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IV Verruc...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVC Saliv...
Stage IVC Squam...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI)
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerNCT01637194
Recurrent Adeno...
Recurrent Basal...
Recurrent Colon...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Stage IV Adenoi...
Stage IV Basal ...
Stage IV Lympho...
Stage IV Lympho...
Stage IV Mucoep...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Squamo...
Stage IV Verruc...
Stage IV Verruc...
Stage IVA Colon...
Stage IVA Esthe...
Stage IVA Inver...
Stage IVA Midli...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVB Colon...
Stage IVB Esthe...
Stage IVB Inver...
Stage IVB Midli...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVC Esthe...
Stage IVC Inver...
Stage IVC Midli...
Stage IVC Saliv...
Stage IVC Squam...
Tongue Cancer
everolimus
cetuximab
pharmacological...
laboratory biom...
18 Years - Fox Chase Cancer Center
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerNCT01816984
Metastatic Squa...
Recurrent Metas...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Verru...
Recurrent Verru...
Salivary Gland ...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Tongue Cancer
PI3K inhibitor ...
cetuximab
18 Years - University of Chicago
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: